...
首页> 外文期刊>Cancer Management and Research >rhTPO combined with chemotherapy and G-CSF for autologous peripheral blood stem cells in patients with refractory/relapsed non-Hodgkin’s lymphoma
【24h】

rhTPO combined with chemotherapy and G-CSF for autologous peripheral blood stem cells in patients with refractory/relapsed non-Hodgkin’s lymphoma

机译:rhTPO联合化学疗法和G-CSF治疗难治性/复发性非霍奇金淋巴瘤患者的自体外周血干细胞

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objective: The mobilization and collection of sufficient autologous peripheral blood stem cells (APBSCs) are important for the fast and sustained reconstruction of hematopoietic function after autologous transplantation. This study aims to evaluate the mobilization effect and safety of thrombopoietin (TPO) combined with chemotherapy + G-CSF for APBSCs in patients with refractory/relapsed non-Hodgkin’s lymphoma. Methods: A total of 78 patients were included in the present study. After receiving mobilization chemotherapy, all patients were randomly divided into two groups: TPO group (n=40), patients were given subcutaneous injection of rhTPO?+?G-CSF, and control group (n=38), patients were given subcutaneous injection of G-CSF. The primary endpoint was the total number of obtained CD34+ cells. The secondary endpoints were the mononuclear cell count, the proportion of target and minimum mobilization, the engraftment time of neutrophils and platelets after APBSCT, the number of platelet and red blood cell infusions, the incidence of infectious fever and fever duration, and TPO-related side effects in patients. Results: TPO participation significantly increased the total CD34+ cell count. A higher proportion of patients in the TPO group achieved the minimum and target CD34+ cells, when compared to the control group. TPO-related adverse events were not observed in either of these groups. In addition, there were no significant differences in engraftment time, the number of platelet and red blood cell transfusions, the incidence of infectious fever, and fever duration between these two groups. Conclusion: TPO combined with chemotherapy + G-CSF can safely and effectively enhance the mobilization effect for APBSCs in patients with refractory/relapsed non-Hodgkin’s lymphoma.
机译:目的:动员和收集足够的自体外周血干细胞(APBSC)对于自体移植后快速,持续地重建造血功能至关重要。这项研究旨在评估难治性/复发性非霍奇金淋巴瘤患者中血小板生成素(TPO)联合化疗+ G-CSF联合治疗APBSC的动员效果和安全性。方法:本研究共纳入78例患者。接受动员化疗后,将所有患者随机分为两组:TPO组(n = 40),患者皮下注射rhTPOβ+?G-CSF,对照组(n = 38),患者皮下注射G-CSF。主要终点是获得的CD34 +细胞总数。次要终点是单核细胞计数,靶标和最小动员比例,APBSCT后中性粒细胞和血小板的植入时间,输注血小板和红细胞的数量,感染性发热和发热持续时间以及与TPO相关患者的副作用。结果:TPO参与显着增加了CD34 +细胞总数。与对照组相比,TPO组中更高比例的患者获得了最小和目标CD34 +细胞。在这两个组中均未观察到TPO相关的不良事件。此外,两组的植入时间,血小板和红细胞输注次数,感染性发烧的发生率以及发烧时间没有显着差异。结论:TPO联合化疗+ G-CSF可以安全有效地提高难治性/复发性非霍奇金淋巴瘤患者对APBSC的动员效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号